Yang Meng

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 4

Top Topics

Neoadjuvant Chemotherapy

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of medical economics

The European journal of health economics : HEPAC : health economics in prevention and care

Health and quality of life outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Rachael Louise Slater, Yizhen Lai, Yichen Zhong, Haojie Li, Yang Meng, Blanca Homet Moreno, James Luke Godwin, Tara Frenkl, Guru P Sonpavde, Ronac Mamtani
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of medical economics 23 (9) (2020)
Ash Bullement, Yang Meng, Miranda Cooper, Dawn Lee, Tara Louise Harding, Chris O'Regan, Raquel Aguiar-Ibanez
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available? Journal of medical economics 22 (3) (2018)
Yang Meng, Nadine Hertel, John Ellis, Edith Morais, Helen Johnson, Zoe Philips, Neil Roskell, Andrew Walker, Dawn Lee
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. The European journal of health economics : HEPAC : health economics in prevention and care 19 (8) (2018)
Yang Meng, Grant McCarthy, Anthony Berthon, Jerome Dinet
Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study. Health and quality of life outcomes 15 (1) (2017)